Gemini Therapeutics (GMTX) Competitors $58.24 -1.71 (-2.84%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends GMTX vs. PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, and CYTKShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Vaxcyte Ascendis Pharma A/S Roivant Sciences Revolution Medicines Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Cytokinetics Vaxcyte (NASDAQ:PCVX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking. Is PCVX or GMTX more profitable? Vaxcyte's return on equity of -23.53% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Gemini Therapeutics N/A -38.78%-35.88% Which has more volatility and risk, PCVX or GMTX? Vaxcyte has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Do insiders & institutionals have more ownership in PCVX or GMTX? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in PCVX or GMTX? Vaxcyte received 26 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave Vaxcyte an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4575.00% Underperform Votes1525.00% Gemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Which has better valuation and earnings, PCVX or GMTX? Gemini Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-18.54Gemini TherapeuticsN/AN/A-$71.87M-$1.00-58.25 Does the media favor PCVX or GMTX? In the previous week, Vaxcyte had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for Vaxcyte and 0 mentions for Gemini Therapeutics. Vaxcyte's average media sentiment score of 0.70 beat Gemini Therapeutics' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media. Company Overall Sentiment Vaxcyte Positive Gemini Therapeutics Neutral Do analysts rate PCVX or GMTX? Vaxcyte currently has a consensus target price of $145.71, suggesting a potential upside of 70.83%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vaxcyte is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryVaxcyte beats Gemini Therapeutics on 12 of the 15 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.52B$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-58.259.9189.4217.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book20.156.055.314.79Net Income-$71.87M$154.90M$122.54M$225.00M7 Day Performance-0.84%1.35%1.42%2.37%1 Month Performance-9.70%0.41%2.51%4.40%1 Year Performance-9.98%3.08%25.29%20.10% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$58.25-2.8%N/A-10.0%$2.52BN/A-58.2530PCVXVaxcyte2.2218 of 5 stars$81.17+0.1%$145.71+79.5%+40.8%$10.12BN/A-17.65160Insider TradeASNDAscendis Pharma A/S3.6284 of 5 stars$134.04+3.8%$192.07+43.3%-2.9%$8.13B$327.43M-16.59640Short Interest ↓Analyst RevisionROIVRoivant Sciences3.5443 of 5 stars$10.74+1.0%$17.93+66.9%+7.7%$7.82B$129.13M1.90860Options VolumePositive NewsRVMDRevolution Medicines4.5331 of 5 stars$42.57+1.9%$66.25+55.6%+49.6%$7.16B$742,000.00-11.86250LNTHLantheus4.5393 of 5 stars$94.65-1.3%$131.86+39.3%+72.3%$6.58B$1.50B15.75700BPMCBlueprint Medicines1.8809 of 5 stars$103.36+18.2%$122.72+18.7%+35.8%$6.57B$434.42M-48.99640Short Interest ↑High Trading VolumeBBIOBridgeBio Pharma4.0926 of 5 stars$33.73+16.0%$48.08+42.5%-7.8%$6.37B$217.77M-14.00400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.5813 of 5 stars$32.50-3.3%$80.62+148.0%-42.4%$5.94B$520.18M-34.211,800Short Interest ↓ELANElanco Animal Health4.3844 of 5 stars$11.72+2.5%$16.43+40.2%-17.6%$5.79B$4.45B29.309,800CYTKCytokinetics4.2371 of 5 stars$46.71+0.2%$83.64+79.1%-43.5%$5.51B$7.53M-8.68250 Related Companies and Tools Related Companies Vaxcyte Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Lantheus Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GMTX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
